TNDM Tandem Diabetes Care, Inc. - Common Stock

NAS · US · Healthcare · Medical Devices · tandemdiabetes.com

16.50USD0.00%Mkt Cap: 1.15B $P/E: —3d ago

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery sy…

Industry Peers

Medical Devices

Screen all

ABT

Abbott Laboratories Common Stock

$169.83BUSDP/E 31.6

MDT

Medtronic plc. Ordinary Shares

$110.49BUSDP/E 21.2

SYK

Stryker Corporation Common Stock

$105.65BUSDP/E 28.5

BSX

Boston Scientific Corporation Common Stock

$61.74BUSDP/E 17.2

Edwards Lifesciences Corporation Common Stock

$49.03BUSDP/E 50.7

SHL

Siemens Healthineers AG

$46.06BUSDP/E 19.2

DXCM

DexCom, Inc. - Common Stock

$32.21BUSDP/E 33.7

GEHC

GE HealthCare Technologies Inc. - Common Stock

$29.24BUSDP/E 14.8

PHG

Koninklijke Philips N.V. NY Registry Shares

$23.38BUSDP/E 18.5

PHIA

Koninklijke Philips N.V.

$22.60BUSDP/E 18.7

STE

STERIS plc (Ireland) Ordinary Shares

Zimmer Biomet Holdings, Inc. Common Stock

$16.84BUSDP/E 21.4

PEN

Penumbra, Inc. Common Stock

$12.51BUSDP/E 77.8

TXG

10x Genomics, Inc. - Common Stock

$12.18BUSD

SNN

Smith & Nephew SNATS, Inc. Common Stock

Globus Medical, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc. Class A Common Stock

$9.88BUSDP/E 45.0

Key Statistics

Company

Market Cap1.15B USD

Enterprise Value1.43B USD

Revenue (TTM)1.04B USD

Gross Profit546.01M USD

Net Income (TTM)-204.71M USD

Revenue/Share15.25 USD

Last Price16.50 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees2.5K

CountryUS

SectorHealthcare

IndustryMedical Devices

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)96.66

PEG—

EV/EBITDA-57.18

EV/Revenue1.37

P/S1.10

P/B8.80

EPS (TTM)-0.91

EPS (Forward)0.17

52W Range

11.4628% of range29.65

52W High29.65 USD

52W Low11.46 USD

Profitability

Gross Margin53.81%

Oper. Margin-5.42%

EBITDA Margin-2.40%

Profit Margin-20.17%

ROE-131.93%

ROA-23.23%

Growth

Revenue Growth5.80%

Earnings Growth—

Cash Flow & Leverage

Operating CF-9.72M USD

CapEx (TTM)98.54M USD

FCF Margin-4.22%

FCF Yield-3.83%

Net Debt283.26M USD

Net Debt/EBITDA-11.32

Balance Sheet

Debt/Equity2.86

Current Ratio3.18

Quick Ratio2.44

Book Value/Sh1.88 USD

Cash/Share6.55 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay DateOct 10, 2017

Splits

Last Split1:10

Split DateOct 10, 2017

Analyst Consensus

Rating2.0 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)28.35 USD

Upside (mean)+71.8%

Target Range18.00 USD – 50.00 USD

18.00+71.8% to mean50.00

# Analysts20

Ownership

Shares Out.69.58M

Float63.76M

Insiders1.17%

Institutions115.90%

Short Interest

Short Ratio8.1d

Short % Float24.01%

Short % Out.17.93%

Shares Short12.47M

Short (prev mo.)10.59M

Technical

SMA 5019.52 (-15.5%)

SMA 20019.44 (-15.1%)

Beta1.56

S&P 52W Chg14.58%

Avg Vol (30d)1.87M

Avg Vol (10d)2.46M

Technical Indicators

RSI (14)39.8

MACD-0.9876

MACD Signal-0.9048

MACD Hist.-0.0828

BB Upper21.35 USD

BB Middle17.68 USD

BB Lower14.02 USD

BB Width41.46%

ATR (14)1.113 USD

Vol Ratio (20d)1.07x